Video

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Author(s):

Matthew D. Galsky, MD

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Yousef Zakharia, MD
Phase 3 AMPLIFY Trial
Nazli Dizman, MD
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Bradley McGregor, MD,
David A. Braun, MD, PhD
RLY-2608
David A. Braun, MD, PhD
Bradley McGregor, MD,
Rohan Garje, MD
Related Content
Toni Choueiri, MD
January 28th 2025

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

US FDA
January 27th 2025

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Felix Y. Feng, MD
January 22nd 2025

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

Urothelial Carcinoma | Image Credit: © Sebastian Kaulitzki- stock.adobe.com
January 22nd 2025

UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC